CYTOCHROME P-450 3A4: Regulation and Role in Drug Metabolism

Annual Review of Pharmacology and Toxicology - Tập 39 Số 1 - Trang 1-17 - 1999
F. Peter Guengerich1
1Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA. [email protected]

Tóm tắt

▪ Abstract  Cytochrome P-450 (P-450) 3A4 is the most abundant P-450 expressed in human liver and small intestine. P-450 3A4 contributes to the metabolism of approximately half the drugs in use today, and variations in its catalytic activity are important in issues of bioavailability and drug-drug interactions. The gene is known to be inducible by barbiturates, glucocorticoids, and rifampicin in humans and in isolated hepatocytes, although the mechanism remains unclear. The 5′-untranslated region includes putative basal transcription element, hepatocyte nuclear factor, p53, AP-3, glucocorticoid regulatory element, pregnane X receptor, and estrogen receptor element sequences. Recently, the GRE element has been shown to act in a classic glucocorticoid response. Several issues remain to be resolved regarding the catalytic activity of the P-450 3A4 protein, including rate-limiting steps and the need for cytochrome b5, divalent cations, and acidic phospholipid systems for optimal activity. Another issue involves the basis of the homotropic and heterotropic cooperativity seen with the enzyme. The in vivo significance of these findings remains to be further established. In addition to more basic studies on P-450 3A4, several areas of practical interest to the pharmaceutical industry require development.

Từ khóa


Tài liệu tham khảo

10.3109/10408449209145319

10.3109/03602539508998329

Guengerich FP. 1995. Human cytochrome P-450 enzymes. InCytochrome P-450, ed. PR Ortiz de Montellano, pp. 473–535. New York: Plenum. 2nd ed.

Leeder JS, Okey AB. 1996. Cytochromes P-450 and liver injury. InDrug Induced Hepatotoxicity, ed. RG Cameron, G Feuer, FA de la Iglesia, pp. 119–53. Berlin: Springer-Verlag

10.2165/00003088-199426020-00007

10.1016/0024-3205(71)90233-5

10.1016/0003-9861(72)90239-1

Elshourbagy NA, 1980, J. Biol. Chem., 255, 1279, 10.1016/S0021-9258(19)86026-X

10.1021/bi00266a045

10.1021/bi00387a022

10.1093/oxfordjournals.jbchem.a123115

10.1097/00008571-199602000-00002

Bonfils C, 1983, J. Biol. Chem., 258, 5358, 10.1016/S0021-9258(20)81896-1

10.1016/0006-291X(79)91990-9

10.1016/0014-5793(77)80275-5

10.1016/0006-2952(84)90165-5

Guengerich FP, 1986, J. Biol. Chem., 261, 5051, 10.1016/S0021-9258(19)89213-X

10.1016/0003-9861(80)90274-X

10.1021/bi00292a019

10.1073/pnas.83.21.8064

10.1073/pnas.82.18.6310

10.1073/pnas.83.14.5311

Combalbert J, 1989, Drug Metab. Dispos., 17, 197

10.1042/bj2630653

10.1093/oxfordjournals.jbchem.a122081

Bork RW, 1989, J. Biol. Chem., 264, 910, 10.1016/S0021-9258(19)85029-9

10.1016/0006-2952(79)90360-5

10.1021/bi00470a024

10.1172/JCI116607

Aoyama T, 1989, J. Biol. Chem., 264, 10388, 10.1016/S0021-9258(18)81632-5

10.1016/0003-9861(89)90449-9

Wrighton SA, 1989, Mol. Pharmacol., 36, 97

Wrighton SA, 1990, Mol. Pharmacol., 38, 207

10.1006/bbrc.1996.0618

10.1006/abbi.1995.1177

10.1006/abbi.1997.0286

10.1016/0006-2952(88)90238-9

Horsmans Y, 1992, Pharmacology, 71, 258

10.1111/j.1365-2125.1991.tb05552.x

Shimada T, 1994, J. Pharmacol. Exp. Ther., 270, 414

Remmer H, 1957, Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmakol., 237, 296

10.1530/acta.0.0850189

10.1097/00008571-199402000-00002

10.1111/j.1432-1033.1990.tb19140.x

Kocarek TA, 1995, Drug Metab. Dispos., 23, 415

Barwick JL, 1996, Mol. Pharmacol., 50, 10

Madan A, 1997, ISSX Proc., 12, 58

10.1111/j.1432-1033.1993.tb18412.x

10.1006/bbrc.1994.2870

10.1016/0167-4781(92)90520-A

10.1038/nm0198-092

Schuetz EG, 1984, J. Biol. Chem., 259, 2007, 10.1016/S0021-9258(17)43508-3

10.1021/bi00141a015

10.1021/bi00503a018

10.1021/bi00026a020

10.1006/abbi.1993.1401

10.1006/abbi.1997.0378

10.1006/abbi.1995.1235

10.1006/bbrc.1996.0593

10.1111/j.1432-1033.1990.tb19483.x

10.1023/A:1016428304366

10.1006/abbi.1995.1278

10.1016/S0014-5793(96)01196-9

10.1038/nbt0897-784

Beaune P, 1986, Drug Metab. Dispos., 14, 437

Newton DJ, 1994, Drug Metab. Dispos., 23, 154

Wang RW, 1997, Drug Metab. Dispos., 25, 762

10.1016/0006-2952(95)02077-2

Busch CM, Ghosal A, Mishin V, Guengerich FP, Thomas PE. 1998. Characterization of monoclonal antibodies to human cytochrome P-450 (CYP) 3A4/5. Abstr. 12th Int. Symp. Microsomes Drug Oxid., Montpellier, July 20–24, no. 139

10.1016/0006-2952(83)90470-7

10.1021/tx00016a015

10.3109/00498259509061850

10.1021/tx960060b

10.1021/tx00034a019

Butler AM, 1997, J. Pharmacol. Exp. Ther., 280, 966

10.1006/abbi.1998.0659

10.1002/hep.1840120125

10.1146/annurev.pa.36.040196.001113

Schuetz EG, 1996, Mol. Pharmacol., 49, 311

Guengerich FP, 1991, J. Biol. Chem., 266, 10019, 10.1016/S0021-9258(18)99177-5

10.1021/bi9719399

10.1074/jbc.271.44.27438

10.1073/pnas.90.24.11748

10.1006/abbi.1996.0022

10.1021/tx00013a004

10.1074/jbc.271.44.27321

10.1074/jbc.272.47.29643

10.1016/0006-2952(92)90333-E

10.1016/0003-9861(88)90655-8

Huskey SEW, 1995, Drug Metab. Dispos., 23, 1126

10.1021/bi962359z

10.1074/jbc.272.9.5396

10.1002/cpt1977224475

10.1016/0006-291X(78)90616-2

10.1073/pnas.86.2.462

10.1097/00000542-199209000-00011

10.1021/tx00026a009

Wang RW, 1997, Drug Metab. Dispos., 25, 502

10.1021/bi00187a009

Schwab GE, 1988, Mol. Pharmacol., 33, 493

Johnson EF, 1988, J. Biol. Chem., 263, 17672, 10.1016/S0021-9258(19)77889-2

Kuby SA. 1991. A Study of Enzymes, Vol. 1:Enzyme Catalysis, Kinetics, and Substrate Binding, pp. 253–81. Boca Raton, FL: CRC

Seto Y, 1993, J. Biol. Chem., 268, 9986, 10.1016/S0021-9258(18)82162-7

10.1074/jbc.270.10.5014

10.1126/science.7089530

Lee CA, 1996, J. Pharmacol. Exp. Ther., 277, 287

Witherow LE, 1998, ISSX Proc., 12, 26

10.1016/S0092-8674(00)80900-9

Thông tin
Thông tin xuất bản

Annual Review of Pharmacology and Toxicology

Tập 39 Số 1

1-17

Thông tin tác giả